ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

Mayo Clinic, IgniteData collaborate to deploy data transfer platform

IgniteData announced a collaboration with Mayo Clinic to deploy its Archer platform across multiple sites in the U.S., aiming to improve the management of clinical trial data by enhancing the transfer of information from Electronic Health Records to Electronic Data Capture systems.

October 25, 2024

Vol.50 No.40

In Brief

CEORT, Paradigm Health launch PACT Collective, expand clinical trial access and diversity

CEO Roundtable on Cancer and Paradigm Health Inc. announced a strategic partnership to launch the Partnership for Access, Collaboration, and Trust Collective. This pioneering initiative aims to break down barriers and create equitable access to oncology clinical trials, particularly for African American, Hispanic, and other underrepresented patient groups.

October 25, 2024

Vol.50 No.40

Clinical

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

October 18, 2024

Vol.50 No.39

By McKenzie Prillaman

Clinical Trials & Tribulations

Cancer clinical trials shouldn’t discriminate—but they do

In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.

October 11, 2024

Vol.50 No.38

By Erin Miller

In the Archives

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.

October 04, 2024

Vol.50 No.37

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

Mayo Clinic, IgniteData collaborate to deploy data transfer platform

CEORT, Paradigm Health launch PACT Collective, expand clinical trial access and diversity

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

Cancer clinical trials shouldn’t discriminate—but they do

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Renew today!

Subscriber content

Login

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

Mayo Clinic, IgniteData collaborate to deploy data transfer platform

CEORT, Paradigm Health launch PACT Collective, expand clinical trial access and diversity

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo

Cancer clinical trials shouldn’t discriminate—but they do

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Login

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo